NicholaosCBellosMD

PubMed

• Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppre...
  François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel E. Gallant, Eric S. Daar, Keith Henry, Jorge Santana-Bagur, David Stein, Nicholaos C. Bellos, Anthony ...> ;Journal of Acquired Immune Deficiency Syndromes. 2017 Jun 1
• Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
  Skiest, D. J., Cohen, C., Mounzer, K., Haigney, Z., Barker, D., Gottlieb, M. S., Bellman, P. C., Dejesus, E., Khanlou, H., Ruane, P. J., Hsiao, C., Abriola, K., Rashba...> ;HIV clinical trials. 2011 Jun 21
• 33 citations
  Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine pl...
  Squires, K. E., Young, B., Dejesus, E., Bellos, N. C., Murphy, D., Zhao, H. H., Patel, L. G., Ross, L. L., Wannamaker, P. G., Shaefer, M. S.> ;AIDS (London, England). 2010 Jul 9
• 116 citations
  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
  Kimberly Y. Smith, Parul Patel, Derek M. Fine, Nicholaos C. Bellos, Louis Sloan, Philip Lackey, Princy Kumar, Denise H Sutherland-Phillips, Cindy Vavro, Linda Yau, Pau...> ;AIDS. 2009 Jul 31
• 187 citations
  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
  Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N. C., Saag, M. S.,...> ;The New England journal of medicine. 2008 Oct 4
• 1 citation
  T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
  Lalezari, J. P., Bellos, N. C., Sathasivam, K., Richmond, G. J., Cohen, C. J., Myers, R. A., Henry, D. H., Raskino, C., Melby, T., Murchison, H., Zhang, Y., Spence, R....> ;The Journal of infectious diseases. 2005 Mar 5
• 103 citations
  SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
  Joseph Gathe, Prudence Ive, Robin Wood, Dirk Schürmann, Nicholaos C. Bellos, Edwin DeJesus, Andrzej Gladysz, Cindy Garris, Jane Yeo> ;AIDS. 2004 Jul 23
• Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
  Margaret A. Fischl, Alfred F. Burnside, Charles Farthing, Melanie A. Thompson, Nicholaos C. Bellos, Vanessa C. Williams, Teresa L. Kauf, Paul Wannamaker, Mark S. Shaefer> ;Pharmacotherapy. 2003 Nov 1
• 137 citations
  Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
  Squires, K., Pozniak, A. L., Pierone, G., Steinhart, C. R., Berger, D., Bellos, N. C., Becker, S. L., Wulfsohn, M., Miller, M. D., Toole, J. J., Coakley, D. F., Cheng,...> ;Annals of internal medicine. 2003 Sep 11
• 8 citations
  Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
  Sension, M. G., Bellos, N. C., Johnson, J., Sepulveda, G. E., DeJesus, E., Santana, J. L., Ames, M. H., Goodwin, S. D.> ;HIV clinical trials. 2002 Oct 31
• 3 citations
  Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
  Harold A. Kessler, Judy Johnson, Stephen E. Follansbee, Michael Sension, Donna Mildvan, Gladys E. Sepulveda, Nicholaos C. Bellos, Seth Hetherington> ;Clinical Infectious Diseases. 2002 Feb 15
• Join now to see all